1-<(tert-Butyldimethylsilyl)oxy>-2-methyl-1-aza-1,3-butadiene | 190014-75-6

• 分子结构分类: 有机化合物 - 有机金属化合物 - 有机类金属化合物
• 英文名称: 1-<(tert-Butyldimethylsilyl)oxy>-2-methyl-1-aza-1,3-butadiene
• 英文别名: 2-methyl-1-(t-butyldimethylsilyoxy)-1-aza-1,3-butadiene；1-(tert-butyldimethylsilyloxy)-2-methyl-1-aza-1,3-butadiene；1-[(tert-Butyldimethylsilyl)oxy]-2-methyl-1-aza-1,3-butadiene；N-[tert-butyl(dimethyl)silyl]oxybut-3-en-2-imine
• CAS: 190014-75-6
• 化学式: C₁₀H₂₁NOSi
• 分子量: 199.368
• InChiKey: LPPTYCCZGSKLAP-UHFFFAOYSA-N

物化性质

• 沸点：
  189.0±13.0 °C(Predicted)
• 密度：
  0.81±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.57
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  21.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-<(tert-Butyldimethylsilyl)oxy>-2-methyl-1-aza-1,3-butadiene 以 氯苯 、 苯 为溶剂， 以66%的产率得到乙酰胺,N-(5,8-二氢-2-甲基-5,8-二羰基-7-喹啉基)-
  参考文献：
  名称：

  Quinoline-5,8-diones and methods of using them

  摘要：

  这项发明提供了具有以下结构式的喹啉-5,8-二酮：##STR1## 其中X、Z和R^1到R^3在规范中有定义，并且这些喹啉二酮的盐。该发明还提供了制备喹啉二酮的方法。这些喹啉二酮具有抗肿瘤活性。

  公开号：

  US05712289A1
• 作为产物：
  描述：

  O-(叔丁基二甲基硅烷)羟胺 、 丁烯酮 在 4 A molecular sieve 作用下， 以 二氯甲烷 为溶剂， 以71%的产率得到1-<(tert-Butyldimethylsilyl)oxy>-2-methyl-1-aza-1,3-butadiene
  参考文献：
  名称：

  N-甲硅烷氧基1-氮杂二烯的Diels-Alder反应

  摘要：

  新型的1-（叔丁基二甲基甲硅烷氧基）-1-氮杂-1,3-丁二烯1和2是通过O-（叔丁基二甲基甲硅烷氧基）羟胺分别与甲基乙烯基酮和甲基丙烯醛反应制备的。通过共享氧非键电子的氮杂二烯1和2被激活，因此它们与许多卤代苯醌，萘醌和N-苯基马来酰亚胺的Diels-Alder反应区域特异性地给出了各种吡啶杂环的低至良好的收率。

  DOI：

  10.1016/s0040-4039(97)00326-2

文献信息

• Quinoline-5,8-diones and methods of using them
  申请人：Ball State University

  公开号：US05712289A1

  公开（公告）日：1998-01-27

  The invention provides quinoline-5,8-diones having the following formula: ##STR1## wherein X, Z and R.sup.1 through R.sup.3 are defined in the specification, and salts of these quinolinediones. The invention also provides a method of making the quinolinediones. The quinolinediones have antitumor activity.

  这项发明提供了具有以下结构式的喹啉-5,8-二酮：##STR1## 其中X、Z和R^1到R^3在规范中有定义，并且这些喹啉二酮的盐。该发明还提供了制备喹啉二酮的方法。这些喹啉二酮具有抗肿瘤活性。
• Lavendamycin analogs and methods of making and using them
  申请人：——

  公开号：US05525611A1

  公开（公告）日：1996-06-11

  The invention provides lavendamycin analogs having the following formula: ##STR1## wherein X, Y and R.sup.1 through R.sup.9 are defined in the specification, and salts of these analogs. The invention also provides a method of making the lavendamycin analogs. The lavendamycin analogs have antitumor and antimicrobial activity.

  本发明提供了具有以下公式的lavendamycin类似物：## STR1 ## 其中X，Y和R.sup.1到R.sup.9在说明书中定义，并提供这些类似物的盐。本发明还提供了制备lavendamycin类似物的方法。这些lavendamycin类似物具有抗肿瘤和抗微生物活性。
• Methods of using lavendamycin analogs
  申请人：Ball State University

  公开号：US05646150A1

  公开（公告）日：1997-07-08

  The invention provides lavendamycin analogs having the following formula: ##STR1## wherein X, Y and R.sup.1 through R.sup.9 are defined in the specification, and salts of these analogs. The invention also provides a method of making the lavendamycin analogs. The lavendamycin analogs have antitumor and antimicrobial activity. Also, methods of treating cancer using lavendamycin methyl ester, 7-butyramido-2-methylquinoline-5,8-dione or 7-butyramido-2-formylquinoline-5,8-dione.

  本发明提供了具有以下公式的lavendamycin类似物：##STR1## 其中X、Y和R.sup.1到R.sup.9在规范中定义，并提供这些类似物的盐。本发明还提供了制备lavendamycin类似物的方法。这些lavendamycin类似物具有抗肿瘤和抗微生物活性。此外，使用lavendamycin甲酯、7-丁酰胺基-2-甲基喹啉-5,8-二酮或7-丁酰胺基-2-甲酰基喹啉-5,8-二酮的治疗癌症的方法。
• Azepine synthesis via a diels-alder reaction
  申请人：State of Oregon, acting by and through The Oregon State Board of Higher

  公开号：US05476933A1

  公开（公告）日：1995-12-19

  Disclosed are methods of preparing azepines by a multistep synthesis including a Diels-Alder reaction. Also disclosed are methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, inducing anesthesia and treating or preventing opiate tolerance are disclosed by administering to an animal in need of such treatment an azepine which has high binding to the NMDA glycine site.

  本发明涉及通过多步合成，包括Diels-Alder反应制备氮杂环庚烷的方法。还涉及治疗或预防与中风、缺血、中枢神经系统创伤、低血糖和手术相关的神经元丧失的方法，以及治疗包括阿尔茨海默病、肌萎缩性侧索硬化症、亨廷顿病和唐氏综合症在内的神经退行性疾病，治疗或预防兴奋性氨基酸过度活跃的不良后果，以及治疗焦虑、慢性疼痛、惊厥、诱导麻醉和治疗或预防阿片类药物耐受性，通过向需要这种治疗的动物注射具有高亲和力的NMDA甘氨酸位点结合能力的氮杂环庚烷来实现。
• Azepine compounds
  申请人：State of Oregon, Acting by and through The Oregon State Board of Higher

  公开号：US05708168A1

  公开（公告）日：1998-01-13

  Disclosed are methods of preparing azepines by a multistep synthesis including a Diels-Alder reaction. Also disclosed are methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, inducing anesthesia and treating or preventing opiate tolerance are disclosed by administering to an animal in need of such treatment an azepine which has high binding to the NMDA glycine site.

  本发明涉及一种通过多步合成包括Diels-Alder反应制备氮杂环庚烯的方法。同时，本发明还涉及一种通过给予具有高结合NMDA甘氨酸位点的氮杂环庚烯来治疗或预防与中风、缺血、中枢神经系统创伤、低血糖和手术有关的神经元丢失，以及治疗阿尔茨海默病、肌萎缩性侧索硬化、亨廷顿病和唐氏综合征等神经退行性疾病，治疗兴奋性氨基酸过度活跃的不良后果，以及治疗焦虑、慢性疼痛、惊厥、诱导麻醉和治疗或预防鸦片类药物耐受性的方法。